secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0001193125-25-123175
Event type: litigation
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia wins patent litigation for NUPLAZID; court rules for Acadia on infringement and validity
--------------------------------------------------------------------------------

- U.S. District Court for Delaware ruled in Acadia's favor in Pimavanserin II Cases regarding '721 formulation patent for NUPLAZID.
- Court ruled for Acadia on both infringement and validity arguments against Aurobindo Pharma and MSN Laboratories.
- Acadia entered a 12-year lease for ~52,771 sq ft Princeton executive office; 210 Lease starts by Jan 2026 with $1.9M first-year rent.
- Amended current 502 Lease to terminate 5 days after 210 Lease commencement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312525123175/0001193125-25-123175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312525123175/d943674d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-123175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer